Volume 95 Issue 46 | p. 13 | Concentrates
Issue Date: November 20, 2017

CRISPR antibiotics company raises cash

Department: Business
Keywords: Biotechnology, Locus Biosciences, CRISPR, CRISPR/Cas3, Cas3, antibiotics

Locus Biosciences has raised $19 million in a series A funding round to develop antibiotics with CRISPR. While most gene-editing companies are working with CRISPR/Cas9 to make fine-tuned cuts in human DNA, Research Triangle Park, N.C.-based Locus is using a version of CRISPR, called CRISPR/Cas3, that acts more like a chainsaw, tearing up precisely targeted bacterial DNA. Investors include Tencent Holdings, Abstract Ventures, and the North Carolina Biotechnology Center.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment